Neurogene Inc. Payments to Acquire Held-to-maturity Securities
Neurogene Inc. (NGNE) reported Payments to Acquire Held-to-maturity Securities of $196.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2026-08-11
- Neurogene Inc. payments to acquire held-to-maturity securities for the quarter ending 2026-06-30 was $112.68M, a 86.55% increase year-over-year.
- Neurogene Inc. payments to acquire held-to-maturity securities for the quarter ending 2026-03-31 was $83.48M, a 6.17% decline year-over-year.
- Neurogene Inc. payments to acquire held-to-maturity securities for the quarter ending 2025-12-31 was $42.76M, a 63.84% decline year-over-year.
- Neurogene Inc. payments to acquire held-to-maturity securities for the quarter ending 2025-09-30 was $77.38M, a 106.09% increase year-over-year.
- Neurogene Inc. payments to acquire held-to-maturity securities for fiscal 2025 was $269.51M, a 35.81% increase from fiscal 2024.
- Neurogene Inc. payments to acquire held-to-maturity securities for fiscal 2024 was $198.45M.
- Neurogene Inc. payments to acquire held-to-maturity securities for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $112.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $196.16M 10-Q · filed 2026-08-11 | $238.92M derived: sum of 3 quarters · filed 2026-08-11 | $316.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $83.48M 10-Q · filed 2026-05-12 | $126.24M derived: sum of 2 quarters · filed 2026-05-12 | $203.63M derived: sum of 3 quarters · filed 2026-05-12 | $264.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $42.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $120.15M derived: sum of 2 quarters · filed 2026-03-24 | $180.55M derived: sum of 3 quarters · filed 2026-08-11 | $269.51M 10-K · filed 2026-03-24 |
| 2025-09-30 | $77.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $137.78M derived: sum of 2 quarters · filed 2026-08-11 | $226.75M 10-Q · filed 2025-11-13 | $345.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $60.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $149.37M 10-Q · filed 2026-08-11 | $267.62M derived: sum of 3 quarters · filed 2026-08-11 | $305.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $88.97M 10-Q · filed 2026-05-12 | $207.22M derived: sum of 2 quarters · filed 2026-05-12 | $244.76M derived: sum of 3 quarters · filed 2026-05-12 | $287.42M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $118.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $155.80M derived: sum of 2 quarters · filed 2026-03-24 | $198.45M derived: sum of 3 quarters · filed 2026-03-24 | $198.45M 10-K · filed 2026-03-24 |
| 2024-09-30 | $37.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $80.20M derived: sum of 2 quarters · filed 2025-11-13 | $80.20M 10-Q · filed 2025-11-13 | $80.20M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $42.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $42.65M 10-Q · filed 2025-08-11 | $42.65M derived: sum of 3 quarters · filed 2025-08-11 | $42.65M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-09 | $0.00 derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $0.00 10-K · filed 2025-03-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $0.00 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |